Pubblicazioni

1311P The role of inflammatory biomarkers in advanced non-small cell lung cancer patients treated with chemo-immunotherapy

2021 - ANNALS OF ONCOLOGY

Zattarin, E.; Manglaviti, S.; Galli, E.; Apollonio, G.; Beninato, T.; Mazzeo, L.; Massa, G.; Bottiglieri, A.; Ganzinelli, M.; Proto, C.; Ferrara, R.; Prelaj, A.; Galli, G.; De Toma, A.; Brambilla, M.; Occhipinti, M.; Garassino, M. C. C.; De Braud, F. G. M.; Lo Russo, G.

1236P Poziotinib in NSCLC harbouring EGFR or HER2 exon 20 insertion mutation

2021 - ANNALS OF ONCOLOGY

Prelaj, A.; Bottiglieri, A.; Galli, E.; Lo Russo, G.; Ferrara, R.; Galli, G.; De Toma, A.; Brambilla, M.; Occhipinti, M.; Manglaviti, S.; Beninato, T.; Zattarin, E.; Apollonio, G.; Ganzinelli, M.; Gallucci, R.; Di Mauro, R. M.; de Braud, F.; Torri, V.; Garassino, M. C. C.; Proto, C.

1388P Poziotinib in advanced NSCLC with EGFR or HER2 exon 20 insertion mutation: Initial results from a single site expanded access program

2020 - ANNALS OF ONCOLOGY

Prelaj, A.; Bottiglieri, A.; Proto, C.; Lo Russo, G.; Signorelli, D.; Ferrara, R.; Galli, G.; De Toma, A.; Viscardi, G.; Brambilla, M.; Lobefaro, R.; Manglaviti, S.; Occhipinti, M.; Labianca, A.; Gallucci, R.; Molino, G.; Zilembo, N.; Greco, F. G.; Torri, V.; Garassino, M. C.

IgM-rheumatoid factor as a novel biomarker for a reduced survival in anti-PD-1 treated NSCLC patients through the decrease of CD137+T-cells

2020 - ANNALS OF ONCOLOGY

Ugolini, A; Zizzari, Ig; Ceccarelli, F; Botticelli, A; Colasanti, T; Strigari, L; Rughetti, A; Rahimi, H; Conti, F; Valesini, G; Marchetti, P; Nuti, M

A real-life multicenter study on body weight loss and body mass index in advanced Gastric Cancer patients treated with Ramucirumab-based second-line therapy

2019 - ANNALS OF ONCOLOGY

Parisi, A.; Cortellini, A.; Roberto, M.; Venditti, O.; Santini, D.; DellâAquila, E.; Stellato, M.; Marchetti, P.; Occhipinti, M.; Zoratto, F.; Mazzuca, F.; Tinari, N.; De Tursi, M.; Iezzi, L.; Natoli, C.; Ratti, M.; Pizzo, C.; Ghidini, M.; Ficorella, C.; Cannita, K.

M8Concomitant versus sequential Fotemustine and Bevacizumab in recurrent malignant gliomas: treatment response and survival outcomes in a retrospective analysis

2017 - ANNALS OF ONCOLOGY

Prelaj, A; Rebuzzi, S E; GirÃ²n BerrÃ¬os, J R; Pecorari, S; Fusto, C; Ferrara, C; Salvati, M; Tomao, S; Bianco, Vito

S47A retrospective analysis to evaluted the off-label use Bevacizumab in recurrent malignant gliomas

2016 - ANNALS OF ONCOLOGY

Prelaj, A.; Rebuzzi, S. E.; Salvati, M.; Pozzi, Carolina; Ferrara, C.; Tomao, S.; Bianco, V.

P-158Radioembolization (SIRT) as a Consolidation Treatment in Colorectal Liver Metastases after First Line Chemotherapy: Efficacy Safety

2016 - ANNALS OF ONCOLOGY

Cortesi, E.; Masi, G.; Mancini, M.; Caponnetto, S.; Urbano, F.; Mosillo, C.; Scagnoli, S.; Notarianni, E.; Pelle, G.; Vivaldi, C.; Falcone, A.; Cianni, R.

Prolactin as a potential negative predictive factor in metastatic non-small cell lung cancers (NSCLC) patients in treatment with Nivolumab (NIVO)

2016 - ANNALS OF ONCOLOGY

Caponnetto, S.; Mancini, M.; Manai, C.; Magri, V.; Iannantuono, G. M.; Pellegrino, D.; Mosillo, C.; Piesco, G.; Pomati, G.; Scagnoli, S.; Urbano, F.; Verkhovskaya, S.; Barchiesi, G.; Zancla, S.; Cortesi, E.

Quantification of circulating cell-free DNA by fluorimetry (Qubit) and spectrophotometry (NanoDrop) in patients with malignant melanoma and prostate cancer

2016 - ANNALS OF ONCOLOGY

Ponti, Giovanni; Maccaferri, M; Depenni, Roberta; Mandrioli, Mauro; Pellacani, Giovanni; Manfredini, M; Ozben, T; Ruini, C; Iattoni, Elena; Cerioli, Davide; Cascinu, Stefano; Tomasi, Aldo

E50Safety and toxicity in elderly patients in treatment for metastatic colon cancer

2015 - ANNALS OF ONCOLOGY

Mancini, M.; Mosillo, C.; Caponnetto, S.; Urbano, F.; Manai, C.; Modica, D.; Scagnoli, S.; Cortesi, E.